References
- Rang HP, Dale MM, Ritter JM, Moore PK. (2003). Cancer Chemotherapy. Pharmacology. 5th ed. Oxford: Churchill Livingstone, 693–707.
- Spinger CJ, Duvaz IN. (1995). Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Design, 10:361–372.
- Chabner BA, Allegra CJ, Curt GA, Calabresi P. (1996). Goodman and Gilman’s The pharmacological basis of therapeutics, Antineoplastic agents. New York, U.S.A: McGraw-Hill, 1233–1257.
- Carl PL, Chakravarty PK, Katzenellenbogen JA. (1981). A novel connector linkage applicable in prodrug design. J Med Chem, 24:479–480.
- Connors TA. (1978). Antitumour drugs with latent activity. Biochemie, 60:979–987.
- Bagshawe KD. (1989). The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer, 60:275–281.
- Senter PD, Springer CJ. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev, 53:247–264.
- de Groot FM, Damen EW, Scheeren HW. (2001). Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem, 8:1093–1122.
- Springer CJ, Duvaz IN. (1996). Gene-directed enzyme prodrug therapy (GDEPT): Choice of Prodrugs. Adv Drug Delivery Rev, 22:351–364.
- Harikrishna D, Raghavendra SN, Venkateshwarlu Y, Raghuram Rao A, Rama Krishna D. (2007). β-Galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy. Arch Pharm Res, 30:723–732.
- Devalapally H, Rajan KS, Akkinepally RR, Devarakonda RK. (2008). Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm, 34:789–795.
- Ghosh AK, Khan S, David F. (1999). A β-galactoside phosphoramide mustard prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Chem Commun, 2527–2528.
- Ravindranathan KP, Harold JJ. (1990). A simplified one pot preparation of acetobromosugars from reduced sugars. J Carbohydrate Chem, 9:777–781.
- Bollenback GN, Long JW, Benjamin DG, Lindquist JA. (1955). The synthesis of aryl-d-glucopyranosiduronic acids. J Am Chem Soc, 77, 3310–3315.
- Leu YL, Chen CS, Wu YJ, Chern JW. (2008). Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J Med Chem, 51:1740–1746.
- Vogel Brian, SF, Antony JH, Peter WGS, Austin RT. (1989). Vogel’s text book of practical organic chemistry. 5th ed. New York: Longman Scientific & technical, 960–975.
- Ghosh AK, David F. (1997). A methyl glucuronate prodrug of phosphoramidic mustard. Tetrahedron Lett, 38:8795–8798.
- David NP. (2011). AP5346 (ProLindac™), A DACH platinum polymer conjugate in phase II trials against ovarian cancer. Current Bioactive Compounds, 7:21–26.
- David AW, Thomas LL. (2005). Foye’s Principles of medicinal chemistry, Cancer chemotherapy. 5th ed. India: Lippincott Williams & Wilkins, 924–950.
- Ghosh AK, Khan S, Maini F, Nelson JA, David F. (2000). A daunorubicin β-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapy (GDEPT). Tetrahedron Lett, 41:4871–4874.
- HariKrishna D, Rao AR, Krishna DR. (2003). Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drug News Perspect, 16:309–318.
- Boyer MJ, Tannock IF. (1993). Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res, 60:269–291.
- Singh Y, Palombo M, Sinko PJ. (2008). Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem, 15:1802–1826.
- Chen Y, Hu L. (2009). Design of anticancer prodrugs for reductive activation. Med Res Rev, 29:29–64.
- Greenwald RB, Pendri A, Conover CD, Lee C, Choe YH, Gilbert C et al. (1998). Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg Med Chem, 6:551–562.
- Knox RJ, Connors TA. (1997). Prodrugs in Cancer Chemotherapy. Pathol Oncol Res, 3:309–324.
- Dosio F, Stella B, Arpicco S, Cattel L. (2011). Macromolecules as taxane delivery systems. Expert Opin Drug Deliv, 8:33–55.